先見基因科技

先見基因科技 is dedicated to precision medicine, delivering high-quality and innovative services that open a new era of personalized healthcare. For anyone seeking answers hidden in their DNA, the company combines cutting-edge sequencing technology with expert analysis to turn complex genomic data into clear, actionable insights.

Founded in 2014, 先見基因科技 grew out of academic research and maintains a technology transfer partnership with National Cheng Kung University. This strong scientific foundation allows the company to specialize in a wide range of gene sequencing platform technologies and big data analysis, tailoring sequencing platforms and customized testing analysis to the distinct needs of both research communities and the mass market.

In 2018, 先見基因科技 became the first to bring the Affymetrix GeneTitan automated multi-genome site chip detection platform out of the research world and into the mass market. This platform is the first automated system built with Asian-specific chips, capable of simultaneously detecting more than 750,000 genomic sites in a single run.

By combining genomic medicine with AI big data analysis, 先見基因科技 provides precise and rapid gene testing services. Whether you are a researcher pushing the boundaries of science or an individual taking charge of your health, you get accurate results faster, with the confidence that comes from Asian-optimized detection and intelligent data interpretation.